@article {de Argila:2007:1173-2563:765,
	author = "de Argila, Carlos Martin",
	author = "Ponce, Julio",
	author = "Marquez, Emilio",
	author = "Plazas, M Jose",
	author = "Galvan, Jordi",
	author = "Heras, Joan",
	author = "Porcel, Joana",
	title = "Acceptability of Lansoprazole Orally Disintegrating Tablets in Patients with Gastro-Oesophageal Reflux Disease: ACEPTO Study",
	journal = "Clinical Drug Investigation",
	volume = "27",
	year = "2007",
	abstract = "<B>Objective:</B> To assess the acceptability of lansoprazole orally disintegrating tablets (LODT) in patients with gastro-oesophageal reflux disease (GORD).<P></P><B>Methods:</B> A multicentre, observational, cross-sectional study of patients diagnosed with GORD aged &#8805;18 years under the care of 272 gastroenterologists. Acceptability was determined by global patient assessment whereby the drug's organoleptic characteristics and properties were evaluated by a self-administered 11-item <I>ad hoc</I> questionnaire with a 5-point Likert-type scale.<P></P><B>Results:</B> A total of 734 patients (mean age 49.6 years [SD = 15.2]) with GORD who had been prescribed LODT &#8805;14 days prior to inclusion in the study were evaluable for the main endpoint. Of these, 51.1% were men. Most patients (80.7%) had been treated with doses of LODT 30mg/day for an average of 52.7 days (SD = 59.3). Overall, 93.6% of patients rated LODT treatment as `very acceptable' or ``acceptable'. The degree of acceptability was associated with the perception that the formulation helps treatment compliance (p &#60; 0.001). The drug's properties were rated as follows: size `neither large nor small' (70.0%); flavour `very pleasant' or `pleasant' (75.2%); intensity of flavour `neither strong nor mild', `mild' or `very mild' (86.1%); no `sandy sensation' (53.4%); speed of dissolving `fast' or `very fast' (80.2%); use of tablets `very easy' or `easy' (92.4%) and use of tablets `very convenient' or `convenient' (91.0%). Three adverse reactions, none of them serious, were reported in three patients (0.4%).<P></P><B>Conclusions:</B> LODT were well accepted by patients with GORD. Patients reported that this formulation improved compliance with therapy. Tolerability was excellent.",
	pages = "765-770(6)",
	url = "http://www.ingentaconnect.com/content/adis/cdi/2007/00000027/00000011/art00003"
}